It would be foolhardy to suggest a yield when the company;s cash flows are going to be significantly short of previous expectation.
Very few people would buy a biotech for yield unless the earnings trajectory was positive.
As you can see from ACR share price - that isnt the case at the moment.
That said - you should watch this stock to see if it develops a base or keeps falling from here.
Once the capital damage is done then the yield will be a nice benefit for anyone willing to hold while company regroups.
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
1.8¢ |
Change
-0.001(5.26%) |
Mkt cap ! $7.339M | |||
| Open | High | Low | Value | Volume |
| 1.9¢ | 1.9¢ | 1.8¢ | $11.58K | 619.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 335415 | 1.8¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 1.9¢ | 516258 | 1 |
View Market Depth
| Last trade - 16.10pm 23/06/2025 (20 minute delay) ? |
| ACR (ASX) Chart |